Evidence map›Paper›PMID 35741820›Full record

ReviewGenes2022

Five-Years Review of

Pascal Pedini, Lugdivine Filosa, Nelly Bichel, Christophe Picard, Monique Silvy, Jacques Chiaroni, Caroline Izard, Laurine Laget, Stéphane Mazières

Open access · goldAbstract readReview
In one paragraph

Review in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Bridging the Gap: High-ResolutionHuman mutation · 2026
    Article
  4. Resolution ofInternational journal of molecular sciences · 2024
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Pascal PediniEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.ORCID 0000-0001-9299-3705
Lugdivine FilosaEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Nelly BichelEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Christophe PicardEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Monique SilvyBiologie des Groupes Sanguins, EFS, CNRS, ADES, Aix Marseille University, 13005 Marseille, France.
Jacques ChiaroniEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Caroline IzardEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Laurine LagetEtablissement Français du Sang Provence-Alpes-Côte d'Azur-Corse, 13005 Marseille, France.
Stéphane MazièresBiologie des Groupes Sanguins, EFS, CNRS, ADES, Aix Marseille University, 13005 Marseille, France.ORCID 0000-0003-1266-4659
Centre National de la Recherche Scientifique · FRÉtablissement Français du Sang · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunohematology laboratories are regularly facing transfusion issues due to serological weaknesses. Altered (partial) RH antigens account for most of them. In some situations,

Indexed as

Rh-Hr Blood-Group SystemAllelesExonsGene FrequencyHaplotypesHumansRHCE protein, humanRh-Hr Blood-Group Systemhaplotype CE effectmolecular biologynew variantsRHCERHCE*ce (1136)RHD*DAU-5

Identifiers

PMID35741820
PMCPMC9222276
OpenAlexW4282923395

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.